By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
13hon MSN
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...
A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...
Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...
If your cancer is not causing any symptoms, is growing slowly, or is small and only in your prostate, your physician may suggest active surveillance or watchful waiting instead of treatment. Active ...
The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk prostate cancer showed a 25-year overall survival rate of 94% and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results